Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Final Thoughts on the Treatment of mCRC

February 26th 2014

Panitumumab, Regorafenib, and Ziv-aflibercept in mCRC

February 26th 2014

Third-Line Treatment Options for mCRC

February 26th 2014

First- and Second-Line Treatment of mCRC in Specific Populations

February 26th 2014

Current Trends in the Treatment of CRC

February 26th 2014

Tumor Profiling in Patients With mCRC

February 26th 2014

New Therapies in Development for mCRC

February 26th 2014

Role of the VEGF Inhibitor Aflibercept in mCRC

February 26th 2014

Role of the Multikinase Inhibitor Regorafenib in mCRC

February 26th 2014

Considerations When Selecting an EGFR Inhibitor in mCRC

February 26th 2014

First- and Later-line Use of Panitumumab in mCRC

February 26th 2014

Treatment of Unresectable RAS Wild-type Metastatic CRC

February 26th 2014

Upfront Bevacizumab and Cetuximab Compared in mCRC

February 26th 2014

Clinical Development of Cetuximab in mCRC

February 26th 2014

Optimizing Treatment With EGFR Inhibitors in CRC

February 26th 2014

Introduction: Expanded RAS Testing in Colorectal Cancer

February 26th 2014

Minimally Invasive Techniques Make Strides in Liver Surgery

February 25th 2014

During the past 15 years, minimally invasive general surgery has rapidly expanded to include laparoscopic and robotic techniques for cholecystectomy, colectomy, gastric weight loss, and other procedures

Dr. Fakih on Angiogenesis Versus EGFR Inhibitors in CRC

February 25th 2014

Marwan G. Fakih, MD, professor, director, Gastrointestinal Medical Oncology, City of Hope, discusses anti-angiogenesis versus anti-EGFR therapy in patients who have RAS wild-type colorectal cancer.

Hopes Revived for Targeting the "Undruggable" RAS Family

February 11th 2014

The members of the RAS oncogene family are central cogs in many different cell-signaling pathways, coordinate a variety of important cellular processes, and are highly mutated in a number of different cancers, including several with extremely poor prognosis.

ALK and ROS1 Lung Cancer Oncogenes May Also Drive Colorectal Cancer

February 7th 2014

Gene rearrangements ALK and ROS1 that are known to drive subsets of lung cancer are also present in colorectal cancer according to a recent study in Molecular Cancer Research.